Inventor · disambiguated record
Jan Grimm
Also filed as: GRIMM JAN · GRIMM JAN M · GRIMM JAN MARKUS
45 granted patents·54 pending applications·296 citations·filing 2004–2025
98Inventor score
Files withNEURIMMUNE HOLDING AG25BIOGEN INT NEUROSCIENCE GMBH13MEMORIAL SLOAN KETTERING CANCER CENTER11UNIV ZUERICH7BIOGEN MA INC5
Top patents by PatentIndex Score
99 records- 0195US9828420B2Method of providing disease-specific binding molecules and targetsUNIV ZUERICH·Filed 2016·Granted Nov 28, 2017·14 cites·22 claims
- 0294US8940272B2Human anti-tau antibodiesNITSCH ROGER·Filed 2011·Granted Jan 27, 2015·31 cites·9 claims
- 0394US7927594B2Antibodies directed against amyloid-beta peptideRINAT NEUROSCIENCE CORP·Filed 2005·Granted Apr 19, 2011·24 cites·21 claims
- 0493US9598484B2Human anti-tau antibodiesBIOGEN MA INC·Filed 2013·Granted Mar 21, 2017·18 cites·182 claims
- 0593US8940276B2Human anti-alpha-synuclein antibodiesWEIHOFEN ANDREAS·Filed 2009·Granted Jan 27, 2015·29 cites·26 claims
- 0692US10202445B2Method of providing disease-specific binding molecules and targetsUNIV ZUERICH·Filed 2017·Granted Feb 12, 2019·7 cites·13 claims
- 0791US10131708B2Methods of treating Alzheimer's diseaseUNIV OF ZUERICH·Filed 2017·Granted Nov 20, 2018·12 cites·88 claims
- 0891US8906367B2Method of providing disease-specific binding molecules and targetsNITSCH ROGER·Filed 2008·Granted Dec 9, 2014·29 cites·21 claims
- 0990US9896504B2Human anti-alpha-synuclein antibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2016·Granted Feb 20, 2018·8 cites·75 claims
- 1090US9605059B2Human anti-tau antibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2014·Granted Mar 28, 2017·12 cites·70 claims
- 1189US11180545B2Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies thereforNEURIMMUNE HOLDING AG·Filed 2019·Granted Nov 23, 2021·3 cites·21 claims
- 1289US10874725B2Method of providing patient specific immune response in amyloidoses and protein aggregation disordersUNIV NEW YORK·Filed 2017·Granted Dec 29, 2020·4 cites·19 claims
- 1389US9670272B2Method of providing disease-specific binding molecules and targetsUNIV OF ZÜRICH·Filed 2012·Granted Jun 6, 2017·14 cites·10 claims
- 1489US9580493B2Anti-α synuclein binding moleculesWEIHOFEN ANDREAS·Filed 2012·Granted Feb 28, 2017·16 cites·58 claims
- 1587US10961322B2Human-derived anti-dipeptide repeats (DPRs) antibodyNEURIMMUNE HOLDING AG·Filed 2019·Granted Mar 30, 2021·2 cites·27 claims
- 1686US10259866B2TDP-43 specific binding moleculesBIOGEN INT NEUROSCIENCE GMBH·Filed 2016·Granted Apr 16, 2019·7 cites·88 claims
- 1785US10301381B2Anti-alpha synuclein binding moleculesBIOGEN INT NEUROSCIENCE GMBH·Filed 2018·Granted May 28, 2019·4 cites·16 claims
- 1885US7807165B2Antibodies directed against amyloid-beta peptide and methods using sameRINAT NEUROSCIENCE CORP·Filed 2005·Granted Oct 5, 2010·5 cites·68 claims
- 1985US2024254256A1Human Anti-SOD1 AntibodiesNEURIMMUNE HOLDING AG·Filed 2024·Application pending·0 cites
- 2084US9975947B2Anti-alpha synuclein binding moleculesBIOGEN INT NEUROSCIENCE GMBH·Filed 2017·Granted May 22, 2018·4 cites·15 claims
- 2184US9587014B2TDP-43 specific binding moleculesBIOGEN INT NEUROSCIENCE GMBH·Filed 2012·Granted Mar 7, 2017·7 cites·33 claims
- 2283US10344080B2Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies thereforNEURIMMUNE HOLDING AG·Filed 2014·Granted Jul 9, 2019·6 cites·22 claims
- 2382US11401325B2Human-derived anti-huntingtin (HTT) antibodies and uses thereofNEURIMMUNE HOLDING AG·Filed 2020·Granted Aug 2, 2022·1 cites·12 claims
- 2482US2024279361A1Human-derived anti-dipeptide repeats (dprs) antibodyNEURIMMUNE HOLDING AG·Filed 2023·Application pending·0 cites
- 2581US10973925B2Methods and compositions for theranostic nanoparticlesUNIV CENTRAL FLORIDA RES FOUND INC·Filed 2016·Granted Apr 13, 2021·2 cites·9 claims
- 2681US9370531B2Method of providing patient specific immune response in amyloidoses and protein aggregation disordersHENCO KARSTEN·Filed 2008·Granted Jun 21, 2016·6 cites·11 claims
- 2780US8425905B2Antibodies directed against amyloid-beta peptide and methods using sameROSENTHAL ARNON·Filed 2012·Granted Apr 23, 2013·3 cites·18 claims
- 2879US9283271B2Human anti-SOD1 antibodiesMONTRASIO FABIO·Filed 2011·Granted Mar 15, 2016·5 cites·21 claims
- 2979US8268593B2Polynucleotides encoding antibodies directed against amyloid-beta peptideROSENTHAL ARNON·Filed 2010·Granted Sep 18, 2012·3 cites·35 claims
- 3078US10882902B2Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereofNEURIMMUNE HOLDING AG·Filed 2018·Granted Jan 5, 2021·1 cites·16 claims
- 3178US10556946B2Human derived anti-Huntingtin (HTT) antibodies and uses thereofNEURIMMUNE HOLDING AG·Filed 2015·Granted Feb 11, 2020·2 cites·15 claims
- 3278US10392447B2Human-derived anti-dipeptide repeats (DPRs) antibodyNEURIMMUNE HOLDING AG·Filed 2015·Granted Aug 27, 2019·2 cites·120 claims
- 3377US10688202B2Metal(loid) chalcogen nanoparticles as universal binders for medical isotopesMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2015·Granted Jun 23, 2020·2 cites·20 claims
- 3477US8022268B2Transgenic animal model for alzheimer's diseaseUNIV ZUERICH·Filed 2008·Granted Sep 20, 2011·5 cites·3 claims
- 3577US2022267471A1Human Anti-SOD1 AntibodiesNEURIMMUNE HOLDING AG·Filed 2022·Application pending·0 cites
- 3677US2022403011A1Method of providing disease-specific binding molecules and targetsUNIV OF ZUERICH·Filed 2022·Application pending·0 cites
- 3775US12234281B2Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies thereforNEURIMMUNE HOLDING AG·Filed 2021·Granted Feb 25, 2025·0 cites·13 claims
- 3875US10450365B2Recombinant human antibodies for therapy and prevention of polyomavirus-related diseasesNEURIMMUNE HOLDING AG·Filed 2017·Granted Oct 22, 2019·2 cites·21 claims
- 3973US12162952B2Human-derived anti-(poly-GA) dipeptide repeat (DPR) antibodyBIOGEN MA INC·Filed 2019·Granted Dec 10, 2024·1 cites·18 claims
- 4073US9771413B2Recombinant human antibodies for therapy and prevention of polyomavirus-related diseasesNEURIMMUNE HOLDING AG·Filed 2014·Granted Sep 26, 2017·2 cites·32 claims
- 4173US2022332808A1Human-derived anti-huntingtin (htt) antibodies and uses thereofNEURIMMUNE HOLDING AG·Filed 2022·Application pending·0 cites
- 4273US2021238265A1Human Anti-Tau AntibodiesBIOGEN INT NEUROSCIENCE GMBH·Filed 2020·Application pending·0 cites
- 4372US2020262895A1Human anti-tau antibodiesBIOGEN MA INC·Filed 2019·Application pending·0 cites
- 4471US11352441B2Human anti-SOD1 antibodiesNEURIMMUNE HOLDING AG·Filed 2019·Granted Jun 7, 2022·0 cites·14 claims
- 4571US10344097B2Human anti-SOD1 antibodiesNEURIMMUNE HOLDING AG·Filed 2016·Granted Jul 9, 2019·1 cites·11 claims
- 4671US10072074B2Human islet amyloid polypeptide (HIAPP) specific antibodies and uses thereofNEURIMMUNE HOLDING AG·Filed 2016·Granted Sep 11, 2018·1 cites·26 claims
- 4771US2025145699A1Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies thereforNEURIMMUNE HOLDING AG·Filed 2025·Application pending·0 cites
- 4871US2025154235A1Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies thereforNEURIMMUNE HOLDING AG·Filed 2025·Application pending·0 cites
- 4970US2019153082A1Method of providing disease-specific binding molecules and targetsUNIV ZUERICH·Filed 2018·Application pending·0 cites
- 5069US11091540B2TDP-43 specific binding moleculesBIOGEN INT NEUROSCIENCE GMBH·Filed 2019·Granted Aug 17, 2021·0 cites·31 claims
Showing the top 50 of 99 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →